STATE OF IOWA DEPARTMENT OF
Health AND Human
SERVICES

# Iowa Medicaid Drug Utilization Review (DUR) Commission

**February 1, 2023**

**Location:** **Teleconference** (Due to Federal PHE Declaration for the COVID-19 Pandemic)
**Time:** 9:30 a.m. – 1:30 p.m. CT

**WebEx Meeting Link:**
https://changehealthcare.webex.com/changehealthcare/j.php?MTID=m5624373fe8bf24cf82c6a83b0132e1d9
**Dial In:** 1-844-245-7693 or 1-650-479-3208
**Meeting Number:** 2534 514 2810
**Meeting Password:** 39jTTqM5fNE

## Final Agenda

1. Welcome & Introductions
    a) Commission Members and Staff
2. Commission Business
    a) Approval of the Minutes
    b) November 2022 DUR Recommendation Letter to DHHS
    c) November 2022 P&T Committee Recommendation to DUR
    d) Follow-Up from Previous Meeting(s)
3. Iowa Medicaid Pharmacy Update
4. Prevalence Report Summaries
    a) Fee-for-Service
    b) Amerigroup
    c) Iowa Total Care
    d) Comparative Summary
5. Public Comment* (Complete Speaker Conflict of Interest Disclosure Form)
    - Verbal - Must pre-register to provide verbal public comment and submit a completed conflict of interest disclosure. Five (5) minute maximum limit.
    - Written - Must submit written comments and a completed conflict of interest disclosure.
    - Reference complete public comment policy here.
    - **All submissions must be received no later than 4:30 p.m. CT January 26, 2023.**
    - Send to info@iadur.org ***Indicate in email if providing written or verbal comment.***
6. Retrospective DUR
    a) Data Presentation(s)
        i. Concurrent Use of Opioids and Sedatives

ii. Underutilization of Beta-Blockers in Heart Failure

b) Proposal(s)

i. Contraindications to Metformin

ii. Underutilization of SGLT2i in Type 2 Diabetes and Chronic Kidney Disease

c) Commission Recommendations for Retrospective DUR Agenda Topics

7. Prospective DUR
   a) 90 Day Supply Limit – Initial Review
8. Break (10 minutes)
9. Prior Authorization
   a) Viloxazine (Qelbree) – Initial Review
   b) Dupilumab (Dupixent) – Initial Review
   c) Gonadotropin-Releasing Hormone (GnRH) Receptor Antagonist, Oral – Initial Review
   d) Janus Kinase Inhibitors – Initial Review
   e) Nebivolol (Bystolic) – Removal of Criteria - Second Review
   f) Potassium Binders – Removal of Criteria – Second Review
   g) Select Topical Psoriasis Agents - Second Review
   h) Initial Days' Supply Limit Override, Benzodiazepines – Second Review
   i) High Dose Opioids – Second Review
10. Miscellaneous
    a) DUR Digest Vol. 35, No. 1 – Second Review
    b) MedWatch

    FDA Approves New HIV Drug for Adults with Limited Treatment Options

    FDA Grants Accelerated Approval for Alzheimer's Disease Treatment

    FDA approves drug combination treatment for adults with asthma
11. Adjournment

*Individuals attending meetings of the DUR Commission shall have an opportunity to address the Commission. This opportunity will be granted once during the open portion of the meeting. In order to accommodate all interested parties, all speakers are requested to limit their comments to **5 minutes or less**. If you represent a drug manufacturer as an employee, as a contractor, as a member of the manufacturer's Speaker Bureau, or by any other means, we expect you to cover your individual product or entire product line in that five-minute time frame. Speakers who represent multiple manufacturers will share their 5 minutes with the other manufacturer representative(s) whose product they are speaking on. Any individual speaking, presenting, or providing written comment for virtual meetings must complete a conflict of interest disclosure. Completed forms must be provided to DUR staff at least one week prior to the scheduled meeting at info@iadur.org. Speakers who fail to submit or turn in their conflict of interest disclosure form late will have their request to speak denied or will not have their comments shared.

**www.iadur.org**

For more information, contact the DUR Project Coordinator, Pamela Smith, R.Ph., at info@iadur.org or (515)974-3131.

**Next Meeting**
**May 3, 2023**
**Location TBD**